NU 578 Controlled Substances, Exam Questions With Complete Solutions, Latest Updated 2024/2025 Graded A+

Codeine - ANSWER abused prescription drug, second-most Comprehensive Drug Abuse Prevention and Control Act - ANSWER Act also known as the Controlled Substance Act (1970) transmuscosal fentanyl only approved for breakthrough cancer pain in opioid tolerant patients - ANSWER actiq dopamine reward circuit - ANSWER addictive drugs all activate the brain's _________ naltrexone - ANSWER after detox, an opioid addict can be rx'd ___________ to discourage renewed opioid abuse for appetite stim - ANSWER AIDS patients use Dronabinol (marinol) used for tx of opioid-induced ileus - ANSWER alvimopan II - ANSWER amphetamines are schedule norepinephrine; dopamine - ANSWER amphetamines work primarily by promoting neuronal release of _________ & ___________, and partly by blocking their reuptake insomnia; weight loss - ANSWER amphetamines, most common adverse effects opioids - ANSWER analgesics, most effective available NU 578 Controlled Substances Quiz, Exam Questions With Complete Solution Updated 2024/2025 Graded A+ extended release morphine - ANSWER avinza none, just supportive treatment - ANSWER barbiturate OD antidote? opioid OD - ANSWER barbiturate OD produces same classic triad of symptoms (resp. depression, coma, pinpoint pupils) as seen with opioids - ANSWER barbiturate tolerant individuals are cross-tolerant to other CNS depressants (alcohol, benzos, general anesthetics) but not with ________ addiction - ANSWER behavior pattern characterized by continued use of a psychoactive substance despite physical, psychologic, or social harm anxiety, insomnia, seizure disorders - ANSWER benzodiazepine principal indications are daytime sedation; anterograde amnesia - ANSWER benzodiazepines adverse effects IV - ANSWER benzodiazepines are classified as Schedule panic disorder, GAD - ANSWER benzodiazepines are primarily for which two anxiety d/o's GABA - ANSWER benzodiazepines produce their actions by enhancing the effects of _____, the principal inhibitory neurotransmitter in the CNS eszopiclone (Lunesta) - ANSWER benzodiazepines-like controlled substace approved for long-term use in insomnia a component of REMS - ANSWER black box warnings methadone, tramadol, buprenorphine (suboxone) - ANSWER bridging agents commonly abused subutex or suboxone SL - ANSWER buprenorphine formulations used in management of opioid addiction increase cardiac work - ANSWER butorphanol (stadol) and nalbuphne (nubain) are contraind. In MI as they 21 - ANSWER butrans transdermal sites must be rotated. No site may be reused within ___ days frequently undertreated, able to be mitigated in 90% of cases with proper dosing/drug therapy (consider adjuvants) - ANSWER cancer pain ORT (opioid risk tool); SOAPP (screener and opioid assessment for patients with pain); DIRE (diagnois, intractability, risk, and efficacy score) - ANSWER chronic opioid therapy candidates can be identified with 50-70% of the time - ANSWER chronic opioid therapy fails issuance & filling of prescriptions - ANSWER code of fed regulations, title 21, section 1306 governs II, V - ANSWER codeine by itself is a schedule ___ CS. In cough meds, it's often schedule ___ adjuvant analgesics - ANSWER complement effects of opioids (in combo with, not in substitution of) establishes regulations for controlled substances for manufacturers, prescribers, pharmacists, and distributors - ANSWER Comprehensive Drug Abuse Prevention and Control Act (1970) Controlled Substance Act - ANSWER Comprehensive Drug Abuse Prevention and Control Act (1970) aka any drug whose use is controlled by fed gov. - ANSWER controlled substance definition actual number & numerical value - ANSWER controlled substance prescriptions require general CNS depressants - ANSWER cross-tolerance does not exist between opioid agonists and various opioid agonists - ANSWER cross-tolerance exists among FALSE - ANSWER DEA only regs dispensing of controlled subs, T or F TRUE - ANSWER depression treatment for individuals that did not respond to other tx may include stimulants, T or F appetite stimulant - ANSWER Dronabinol (marinol benzos; SSRIs - ANSWER drug classes most often used for tx of anxiety disorders methadone - ANSWER drug only available through Opioid Treatment Programs cross-dependence - ANSWER drug that has the ability to support physical dependence on another drug is said to have abuse - ANSWER drug use that is inconsistent with medical or social norms pure opioid agonists - ANSWER drugs that activate mu and kappa receptors, producing analgesia, sedation, euphoria, resp. depression, physical dependence, constipation, and cough supression opioid antagonists - ANSWER drugs that block the mu & kappa receptors to cause reversal of sedation/resp. depression caused by opioid overdose DEA - ANSWER enforcing agency for the Comprehensive Drug Prevention & Control Act 1970 25-50 - ANSWER equianalgesic table: switching opioids (other than fentanyl or methadone), decrease the dose rec. in the table by __________ % to account for polymorphisms or enhanced sensitivity to new opioids Comprehensive Drug Abuse Prevention and Control Act - ANSWER establishes regulations for controlled substances for manufacturers, prescribers, pharmacists, and distributors naloxone auto-injector pen - ANSWER Evzio, aka ____________, was fast-tracked through FDA approval to help prevent OD on rx or illicit opioids avinza - ANSWER extended release morphine is called 100 times more potent than morphine - ANSWER Fentanyl direct heat - ANSWER fentanyl patch use education: warn pts to avoid exposing patch to _______, because doing so can accelerate drug release ARE NOT - ANSWER fentanyl products ARE/ARE NOT interchangeable on an mg-by-mg basis can be used to treat benzo OD - ANSWER Flumazenil a benzo receptor antagonist - ANSWER Flumazenil SHORTER - ANSWER half-life of naloxone is ___________ than half-lives of opioids zohydro - ANSWER hydrocodone sustained-release formulation that has no abuse-deterrent properties and therefore its approval is currently being called to be revoked the emergence of a new pain syndrome refractory to tx & is atypical or unrelated to original pain - ANSWER hyperalgesia cognitive behavior therapy (CBT) - ANSWER insomnia first-line treatment (even if drugs are also employed) code of fed regulations title 21 section 1306 and the United States Code--controlled substances act title 21 section 829 - ANSWER issuance and filling of prescriptions is governed by infrequent - ANSWER Issuance and filling of prescriptions is governed by cns depressants, anticholinergics, hypotensives, MAOIs, & partial agonist opioids - ANSWER major drug groups that can interact with opioids appetite stimulant - ANSWER Marinol (dronabinol) a component of REMS - ANSWER medications guides 48 hours - ANSWER meperidine use should not exceed ________ CYP3A4 inhibitors - ANSWER methadone should be watched in conjunction with these hepatic enzyme inhibitors ECG at initiation of therapy, at 1 month, and annually thereafter - ANSWER methadone therapy should have screening patient medication questionnaire (PMQ), current opioid misuse measure (COMM), prescription drug use questionnaire (PDUQ) - ANSWER misuse during chronic opioid therapy can be identified by a pure opioid antagonist that can be used to discourage renewed opioid abuse in an addict who has undergone detox - ANSWER naltrexone psychologic depedence - ANSWER need that is intense and subjective for a particular psychoactive drug peripheral nerves - ANSWER neuropathic pain results from injury to tissues - ANSWER nociceptive pain results from injury to MORE - ANSWER older adults are MORE/LESS sensitive to drug accum. Due to decline in hepatic metabolism and renal excretion males are at higher risk - ANSWER Opioid abuse by gender partial opioid agonists - ANSWER opioid na ïve patients achieve analgesia with at night - ANSWER opioid OD deaths occur most often cronic pain pts. On long-term therapy and those using non-medically - ANSWER opioid OD highest risk patient pops coma, resp. depression, & pinpoint pupils - ANSWER opioid OD: classic triad of symptoms 1 to 4 - ANSWER opioid therapy initiation (or dose escalation) for chronic pain, clinicians should evaluate benefits/harms w/in _____ weeks FALSE - ANSWER opioid therapy initiation, clinicians should rx highest effective dose, T or F anticholinergic - ANSWER opioid use and __________ drug use should be avoided due to exacerbation of opioid-induced constipation and urinary retention constipation or miosis - ANSWER opioid use, no tolerance will develop related to partial opioid agonists - ANSWER opioid users go into withdrawal with use of yawning, rhinorrhea, sweating, anorexia, irritability, tremor, gooseflesh, sneezing, weakness, n/v/d, muscle spasms - ANSWER opioid withdrawal symptoms alvimopan (entereg) - ANSWER opioid-induced ileus treatment hydrocodone, oxycodone, methadone - ANSWER opioid-related deaths, majority of, are due to increased use of dull, constant pain - ANSWER opioids are better at relieving sharp, intermittent pain - ANSWER opioids are not as good at relieving sexual dysfunction; hypogonadism - ANSWER opioids given by intrathecal, transdermal, & sustained release may cause